<p><em>Ilex hainanensis Merr</em> targets ITGAV to suppress the proliferation and metastasis of osteosarcoma cells</p>

Abstract

Background: Osteosarcoma (OS) is the most common primary malignant bone tumor. Hence, there is an urgent need to identify effective and safe therapeutic agents against OS. It has been reported that Ilex hainanensis Merr (IME) possesses antitumor properties. Integrin subunit alpha V (ITGAV) is important for the diagnosis, treatment, and prognosis of tumors. Purpose: The objective of this study was to whether IME can play a role in the treatment of osteosarcoma by regulating ITGAV. Methods: Western blot and real-time PCR were used to detect the expression of ITGAV in non-tumorous tissues, osteosarcoma tissues, and metastatic tumors. The expression of ITGAV in MG63, U2OS, and hFOB1. A total of 19 cells was determined through Western blotting and real-time PCR. The expression of ITGAV in OS cells treated with different concentrations of DDP was determined through Western blotting. Agter transfecting with control or si-ITGAV, and subsequently treated with control or 5 μmol/L DDP, MTT assay and transwell assay were used to detect the proliferaion and migration of cells. Western blot was used to detect the expression of ITGAV in cells treated with different concentrations of IME and MTT assay and transwell assay were used to detect the proliferaion and migration of cells. MG63 and U2OS cells were treated with control, 5 μmol/L DDP, 25 μmol/L IME, or 5 μmol/L DDP combined with 25 μmol/L IME, the expression of ITGAV was determined through Western blotting and real-time PCR. MTT assay and transwell assay were used to detect the proliferation and migration of cells. Inhibitory effect of IME on lung metastasis of osteosarcoma in vivo. Results: ITGAV was highly expressed in tumors, with the highest expression found in metastatic tumors and higher in OS cells. A low concentration of DDP (5 μmol/L) inhibited the expression of ITGAV. However, ITGAV may be related to the development of resistance to DDP. Silencing of ITGAV downregulates the proliferation and migration of OS cells as the effect of low-concentration DDP (5 μmol/L). IME inhibited the proliferation and migration of MG63 and U2OS cells in a concentration-dependent manner and decreased the expression of ITGAV. MTT and Transwell assays showed that 25 μmol/L IME and 5 μmol/L DDP exhibited similar inhibitory effects on the proliferation and migration of OS cells. The combination of IME with DDP resulted in the amplification of these inhibitory effects. Both DDP and IME downregulated the expression of ITGAV, and the inhibition of ITGAV was amplified by the combination of IME with DDP. In-vivo studies have shown that IME and DDP, independently or in combination, may significantly inhibit the metastasis of OS to the lungs. Conclusion: IME may reduce the resistance of OS cells to DDP to some extent.

Long Non-coding RNA SNHG17 Promotes Cell Proliferation and Invasion in Castration-Resistant Prostate Cancer by Targeting the miR-144/CD51 Axis

“…Numerous evidence indicates that up-regulation of CD51 is significantly associated with cancer progression and poor prognosis in multiple types of cancers, such as gastric cancer (Wang et al, 2019), osteosarcoma (Pei et al, 2019), colorectal cancer (Flum et al, 2018), and nasopharyngeal carcinoma (Ding et al, 2017). The expressions and functions of CD51 have been shown to be dysregulated in prostate cancer.…”

Silencing lncRNA ZFAS1 or elevated microRNA-135a represses proliferation, migration, invasion and resistance to apoptosis of osteosarcoma cells

“…OS is the most general malignant bone tumor, while an urgent need is required to identify novel effective therapeutic agents for the protection of OS [14]. Evidence has demonstrated that some certain lncRNAs, miRNAs or some certain genes could be involved in the OS growth.…”

Targeting integrin αvβ3 with indomethacin inhibits patient‐derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma

“…Recent studies have shown that ITGAV is highly expressed in osteosarcoma, hepatocellular carcinoma, and oesophageal adenocarcinoma tissues compared to normal tissues. 51 , 52 , 53 Additionally, inhibition of ITGAV has been shown to reduce tumour growth and metastasis in a variety of cancers. 54 , 55 , 56 Herein, we observed that ITGAV was highly expressed in human ESCC tissues (Figure 1A–C ) and that increased ITGAV levels were related with poor overall survival (Figure 1D ).…”

“…Recent studies have shown that ITGAV is highly expressed in osteosarcoma, hepatocellular carcinoma, and oesophageal adenocarcinoma tissues compared to normal tissues 51–53 . Additionally, inhibition of ITGAV has been shown to reduce tumour growth and metastasis in a variety of cancers 54–56 .…”